Vertaling van "program for antibiotics and other " (Nederlands → Frans) :

62. Evans RS, Pestotnik SL, Classen DC, Clemmer TP et al: A computer-assisted management program for antibiotics and other anti-infective agents.
62. Evans RS, Pestotnik SL, Classen DC, Clemmer TP et al : A computer-assisted management program for antibiotics and other anti-infective agents.

16. Mc Gowan JE Jr: Do intensive hospital antibiotic control programs prevent the spread of antibiotic resistance?
16. Mc Gowan JE Jr : Do intensive hospital antibiotic control programs prevent thé spread of antibiotic resistance ?

43. Achusim LE: Antibiotic use following implementation of a therapeutic interchange program.
43. Achusim LE : Antibiotic use following implémentation of a therapeutic interchange program.

3.3 Testing of other antibiotics for MRSA All MRSA isolates should be reported as resistant to all ß-lactam antibiotics, including ß-lactam/ ß- lactamase inhibitor combinations, cephalosporins and carbapenems.
3.3 Test d’autres antibiotiques pour MRSA Tous les isolats de MRSA doivent être rapportés comme résistants à tous les antibiotiques ß-lactame, en ce compris des combinaisons ß-lactame / inhibiteur de ß-lactamase, des céphalosporines et des carbapénèmes.

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

It is not advised to test other penicillins, ß -lactam inhibitor combinations, cephems or carbapenems in vitro 27 because these antibiotics may appear active in vitro on MRSA and can dangerously mislead the clinician.
Il n’est pas conseillé de tester d'autres pénicillines, des combinaisons d'inhibiteurs de ß-lactame, des céphèmes ou des carbapénèmes in vitro 27 parce que ces antibiotiques pourraient paraître actifs in vitro sur MRSA et induire ainsi dangereusement le clinicien en erreur.

A program called ‘Under the shelter of Novartis’ launched in 2004 in Mexico has offered support through the donation of medicines, meals and other items as well as by offering free medical check-ups.
Au Mexique, un projet initié en 2004 (« Under the shelter of Novartis ») propose un soutien sous plusieurs formes : dons de médicaments, de repas ou d’autres objets, ainsi que check-ups gratuits.

Data from the ASPIRE HIGHER outcomes program and various single-pill combinations with other medicines are expected to drive future growth.
Les données du programme de résultats ASPIRE HIGHER et diverses associations avec d’autres médicaments en un comprimé unique devraient soutenir sa croissance future.

R&D investments (+1.0 percentage points) were lower as productivity initiatives more than offset investments in development programs for biosimilars as well as other differentiated generics, including oncology injectables and respiratory products.
Les investissements en R&D (+1,0 point de pourcentage) ont diminué car les gains de productivité ont plus que compensé les investissements dans les programmes de développement de biosimilaires ainsi que d’autres génériques différenciés, comprenant les injectables en oncologie et les produits contre les maladies des voies respiratoires.

Cost of Goods Sold absorbed 0.6 percentage points, other income and expenses were positive 1.4 percentage points, while productivity programs generated 3.1 percentage points, with approximately 1.7 percentage points being reinvested.
Le Coût des ventes a absorbé 0,6 point de pourcentage, Autres produits et charges ont dégagé 1,4 point tandis que les programmes de productivité ont engendré 3,1 points, dont 1,7 point environ a été réinvesti.